This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cel-Sci's South Africa Partner a Mystery

VIENNA, Va. ( TheStreet) -- The company picked by Cel-Sci Corp. (CVM - Get Report) to market its cancer drug Multikine in South Africa was incorporated just days before the deal was announced in March and appears to have no business address or history of engaging in drug development or marketing.

On March 6, Cel-Sci granted an exclusive license to Byron Biopharma to market and distribute Multikine -- an experimental drug that has yet to begin a pivotal, phase III clinical trial -- in South Africa.

As part of this marketing partnership, Byron Biopharma was allowed to defer a license payment for Multikine. Cel-Sci also sold deeply discounted stock to Byron that has already net the latter company more than $7 million in investment profits on paper.

"This agreement is consistent with our strategy to license Multikine in the emerging markets to share the expenses of bringing Multikine to market. We are working on additional agreements around the world," said Cel-Sci CEO Geert Kersten, in a statement that highlighted the agreement at that time.

Cel-Sci did not respond to questions for this article.

Multikine is a cancer immunotherapy, or cancer "vaccine," that Cel-Sci has been developing since the late 1980s. The company recently raised money from investors to help fund a phase III study in head and neck cancer patients, although the company has not provided a specific start date for the trial.

Cel-Sci issued a press release on March 9 to announce the Multikine deal with Byron Biopharma for South Africa, but the release didn't provide any details about Byron, didn't recount the company's experience selling drugs, especially overseas, and didn't include a quote from a Byron executive.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CVM $0.50 -3.80%
AAPL $93.42 -0.90%
FB $100.17 -0.82%
GOOG $675.17 -1.30%
TSLA $153.20 6.60%


Chart of I:DJI
DOW 15,557.01 -357.73 -2.25%
S&P 500 1,817.79 -34.07 -1.84%
NASDAQ 4,228.5090 -55.0830 -1.29%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs